Open-label, dose confirmation, and dosimetry study of interstitial 131I-chTNT-1/B MAb for the treatment of recurrent glioblastoma multiforme (GBM): Final results

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2010
This article has no abstract
Epistemonikos ID: bdeb407d4b3fa9b989d45e0c4477c654d800f0f8
First added on: Mar 01, 2025